Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033 – Strong Growth by 2033 with a Focus on Treating Rare Diseases – ResearchAndMarkets.com

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033 – Strong Growth by 2033 with a Focus on Treating Rare Diseases – ResearchAndMarkets.com




Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033 – Strong Growth by 2033 with a Focus on Treating Rare Diseases – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033” has been added to ResearchAndMarkets.com’s offering.


World revenue for the Antisense Oligonucleotide (ASO) Therapeutics Market is forecast to surpass US$6 billion in 2023, with strong revenue growth through to 2033.

Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving Market Growth

The application of antisense oligonucleotides (ASOs) in the treatment of rare genetic disorders is a compelling testament to the transformative power of this therapeutic approach. Rare diseases, often referred to as orphan diseases, are characterized by their low prevalence in the population, making them less attractive for traditional drug development efforts. However, ASOs have emerged as a ray of hope for individuals afflicted by these conditions, driving considerable interest and investment in ASO research and development.

Traditional drug development pathways often face significant hurdles when it comes to rare diseases. The small patient populations make conducting large-scale clinical trials challenging, and the financial viability of developing drugs for such conditions can be questionable. ASOs, with their precision and adaptability, have opened up new possibilities for addressing these challenges.

ASOs can be tailored to target the specific genetic mutations or abnormalities responsible for rare diseases. This personalized approach allows for the development of therapies that directly address the underlying cause of the condition, rather than just managing symptoms. This has the potential to revolutionize the treatment landscape for rare diseases, offering the prospect of effective, disease-modifying treatments where none existed before..

Potential Immunogenicity Response in Some Patients Likely to Challenge Industry Growth

Immunogenicity poses a significant market restraint for the Antisense Oligonucleotide (ASO) Therapeutics Market. While ASOs hold immense promise in treating a range of diseases, the potential to provoke an immune response in some patients can lead to adverse effects and reduced treatment effectiveness.

This immunogenic response may hinder the widespread adoption of ASO therapies and pose challenges in terms of patient safety and regulatory approvals. To mitigate this concern, extensive research and development efforts have been focused on chemical modifications and structural alterations to ASO molecules to reduce their immunogenicity.

Market Dynamics

Market Driving Factors

  • Developments in the Field of Target Specific Precision Medicine Driving the ASO Therapeutics Market
  • Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving the ASO Therapeutics Market
  • Improved Delivery Systems Helps in Unlocking the Full Potential of ASOs, thereby Boosting the Market

Market Restraining Factors

  • Off-target Effects Might Act as a Significant Market Restraint in the Development and Adoption of ASO Therapeutics
  • Potential Immunogenicity Response in Some Patients Might Restrain the ASO Therapeutics Market Growth
  • High Cost of Treatment and Manufacturing of ASO Therapeutics Might Impact the Market Growth Negatively

Market Opportunities

  • Novel Approach to Cancer Therapy Might Offer a Promising Market Opportunity to ASO Therapeutics
  • Pipeline Expansion Stands as a Significant Market Opportunity Within the Realm of ASO Therapeutics
  • In the Field of ASO Therapeutics, the Availability of Regulatory Support is a Significant Market Potential

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, this new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antisense Oligonucleotide (ASO) Therapeutics prices and recent developments.

Segments Covered in the Report

Therapeutic Application

  • Neurological Disorders
  • Genetic Disorders
  • Oncological Disorders
  • Cardiovascular Diseases
  • Others

ASO Chemistry

  • DNA Based ASO
  • RNA Based ASO
  • Gapmer ASO

Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets.

The report also includes profiles for the following leading companies, with a focus on this segment of these companies’ operations:

  • Alector
  • Alnylam Pharmaceuticals
  • Antisense Therapeutics
  • Arrowhead Pharmaceuticals
  • Biogen
  • Bio-Path Holdings
  • Dicerna Pharmaceuticals
  • Geron Corporation
  • GSK
  • iCo Therapeutics
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Roche Holding
  • Sarepta Therapeutics
  • Sterna Biologicals

For more information about this report visit https://www.researchandmarkets.com/r/s6w83s

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900